

**Freedom of Information Act 2000 – FoI/23/356**  
**Dermatology Treatments**

**Information Requested:**

**Q1. How many patients were treated in June 2023 (or latest available month) by the Dermatology department with the following drugs:**

- a) Abrocitinib (Cibinqo) 1
- b) Baricitinib (Olumiant) 1
- c) Dupilumab (Dupixent) 69
- d) Omalizumab (Xolair) 7
- e) Tralokinumab (Adtralza) 2
- f) Upadacitinib (Rinvoq) 3

**Q2. How many patients were treated in June 2023 (or latest available month) by the Respiratory Medicine departments with the following drugs:**

- a) Benralizumab (Fasenra) 35
- b) Dupilumab (Dupixent) 25
- c) Mepolizumab (Nucala) 18
- d) Omalizumab (Xolair) 4
- e) Reslizumab (Cinqaero) 0
- f) Tezepelumab (Tezspire) 18

Please note, all figures have been provided for patients treated in July 2023.